Author: "Sylvie Larrat" / Topic: business.industry - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Sylvie Larrat"' showing total 32 results

Start Over Author "Sylvie Larrat" Topic business.industry

32 results on '"Sylvie Larrat"'

1. Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

Author: Myriam Blanc, Sylvie Larrat, Jean-François Payen, Isabelle Pierre, Marion Le Maréchal, Pascal Poignard, Patricia Pavese, Marlyse Buisson, Olivier Epaulard, Nicolas Terzi, Raphaele Germi, Benjamin Nemoz, Laurence Grossi, Marie Froidure, Julien Lupo, Fanny Quénard, and Anne-Laure Mounayar
Subjects: Microbiology (medical), 2019-20 coronavirus outbreak, biology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Virology, Persistence (computer science), Infectious Diseases, Steroid use, biology.protein, Medicine, Antibody, business
Published: 2022
Full Text: View/download PDF

2. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

Author: Sylvie Larrat, Pascal Poignard, Julien Andreani, Aurélie Truffot, Raphaële Germi, Alban Caporossi, Olivier Epaulard, and Marion Le Maréchal
Subjects: Microbiology (medical), Male, Epidemiology, medicine.drug_class, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, viruses, Expedited, coronaviruses, selection, Infectious and parasitic diseases, RC109-216, Monoclonal antibody, Antibodies, Viral, Melting curve analysis, SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy, respiratory infections, Immunocompromised Host, Research Letter, Medicine, Humans, Aged, Whole genome sequencing, variants, biology, business.industry, SARS-CoV-2, COVID-19, Immunocompromised patient, Immunotherapy, Virology, compartmentalization, zoonoses, Infectious Diseases, coronavirus disease, monoclonal antibody, whole-genome sequencing, Viral evolution, monotherapy, Spike Glycoprotein, Coronavirus, biology.protein, immunotherapy, bamlanivimab, Antibody, business, severe acute respiratory syndrome coronavirus 2
Abstract: A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleotide polymorphisms and whole-genome sequencing. Rapid emergence of spike receptor binding domain mutations was found, associated with a compartmentalization of viral populations.
Published: 2021

3. Evaluation of six commercial SARS-CoV-2 rapid antigen tests in nasopharyngeal swabs: better knowledge for better patient management?

Author: Julien Lupo, Julien Andreani, Marie Roccon, Benjamin Nemoz, Raphaële Germi, Christel Laugier, Patrice Morand, and Sylvie Larrat
Subjects: Rapid Antigen tests, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Concordance, RT-PCR, Sensitivity and Specificity, Article, Antigen, Nasopharynx, Virology, Pandemic, medicine, Humans, Viral shedding, Intensive care medicine, Antigens, Viral, Pandemics, Retrospective Studies, business.industry, SARS-CoV-2, COVID-19, Retrospective cohort study, Triage, Infectious Diseases, business
Abstract: Robust antigen point-of-care SARS-CoV-2 tests have been proposed as an efficient tool to address the COVID-19 pandemic. This requirement was raised after acknowledging the constraints that are brought by molecular biology. However, worldwide markets have been flooded with cheap and potentially underperforming lateral flow assays. Herein we retrospectively compared the overall performance of five qualitative rapid antigen SARS-CoV-2 assays and one quantitative automated test on 239 clinical swabs. While the overall sensitivity and specificity are relatively similar for all tests, concordance with molecular based methods varies, ranging from 75,7% to 83,3% among evaluated tests. Sensitivity is greatly improved when considering patients with higher viral excretion (Ct≤33), proving that antigen tests accurately distinguish infectious patients from viral shedding. These results should be taken into consideration by clinicians involved in patient triage and management, as well as by national authorities in public health strategies and for mass campaign approaches.
Published: 2021

4. Is it possible to hospitalize patients in multiple-bed room without increasing the risk of hospital-acquired influenza? Description of a pragmatic preventive strategy in a French university hospital

Author: Othmane Azzam, Caroline Landelle, Sylvie Larrat, Meghann Gallouche, Marie Reine Mallaret, Patrice Morand, Céline Giner, Fabiana Cazzorla, and Emeline Buet
Subjects: Oseltamivir, Epidemiology, Health Personnel, Detection bias, Beds, Antiviral Agents, Hospitals, University, chemistry.chemical_compound, Health care, Influenza, Human, medicine, Humans, Preventive strategy, business.industry, Health Policy, Public Health, Environmental and Occupational Health, virus diseases, Emergency department, University hospital, medicine.disease, Surgical mask, Infectious Diseases, Physical Barrier, chemistry, Medical emergency, business
Abstract: Background Large inrush of patients through Emergency Department during influenza season can be dramatic. The purpose of this study was to evaluate the impact of an emergency preventive strategy, namely admission of patients with influenza in multiple-bed room with patients free from influenza, on the occurrence of hospital-acquired influenza (HAI). Methods When a patient with an influenza RT-PCR diagnosis was hospitalized in a multiple-bed room, the emergency preventive strategy was applied: selection of non-immunocompromised neighbor, implementation of physical barriers (rigid screen pulled between beds, surgical mask for healthcare workers and visitors), preemptive Oseltamivir therapy for the neighbor. Results From 29/11/2017 to 10/05/2018 a total of 464 hospitalized influenza patients were included; 318 were placed in multiple-bed room and 141 in single room. Emergency preventive strategy was correctly applied for 75.1% of patients in multiple-bed room. A total of 8 exposed neighbors matched HAI definition despite strategy. 7 were already exposed to the case before the set-up of the strategy. Only one case of documented transmission of influenza occurred after application of an incorrect emergency preventive strategy: preventive posology of Oseltamivir was not correct. Conclusions These preliminary results suggest that the occurrence of HAI in multiple-bed rooms can be limited by the implementation of maximum precautions and urge us to promote further evaluation of the strategy. A detection bias should be considered without a systematic neighbors monitoring.
Published: 2021

5. SARS-CoV-2 nosocomial infection acquired in a French university hospital during the 1st wave of the Covid-19 pandemic, a prospective study

Author: Benjamin Nemoz, C. Giner, Meghann Gallouche, A Landoas, Sylvie Larrat, Olivier Epaulard, Patricia Pavese, M.R. Mallaret, Patrice Morand, F Cazzorla, Caroline Landelle, and M Le Maréchal
Subjects: Microbiology (medical), Male, medicine.medical_specialty, media_common.quotation_subject, Health Personnel, Infectious and parasitic diseases, RC109-216, Hospitals, University, COVID-19 Testing, Hygiene, Interquartile range, Pandemic, medicine, Infection control, Humans, Pharmacology (medical), Hand Hygiene, Prospective Studies, Healthcare-associated infection, Prospective cohort study, Pandemics, media_common, Aged, Retrospective Studies, Aged, 80 and over, Cross Infection, Infection Control, Mask, business.industry, SARS-CoV-2, Research, Public Health, Environmental and Occupational Health, Masks, COVID-19, Retrospective cohort study, Outbreak, Middle Aged, Surgical mask, Infectious Diseases, Emergency medicine, Observational study, Female, France, business
Abstract: Background In healthcare facilities, nosocomial transmissions of respiratory viruses are a major issue. SARS-CoV-2 is not exempt from nosocomial transmission. Our goals were to describe COVID-19 nosocomial cases during the first pandemic wave among patients in a French university hospital and compliance with hygiene measures. Methods We conducted a prospective observational study in Grenoble Alpes University Hospital from 01/03/2020 to 11/05/2020. We included all hospitalised patients with a documented SARS-CoV-2 diagnosis. Nosocomial case was defined by a delay of 5 days between hospitalisation and first symptoms. Hygiene measures were evaluated between 11/05/2020 and 22/05/2020. Lockdown measures were effective in France on 17/03/2020 and ended on 11/05/2020. Systematic wearing of mask was mandatory for all healthcare workers (HCW) and visits were prohibited in our institution from 13/03/2021 and for the duration of the lockdown period. Results Among 259 patients included, 14 (5.4%) were considered as nosocomial COVID-19. Median time before symptom onset was 25 days (interquartile range: 12–42). Eleven patients (79%) had risk factors for severe COVID-19. Five died (36%) including 4 deaths attributable to COVID-19. Two clusters were identified. The first cluster had 5 cases including 3 nosocomial acquisitions and no tested HCWs were positive. The second cluster had 3 cases including 2 nosocomial cases and 4 HCWs were positive. Surgical mask wearing and hand hygiene compliance were adequate for 95% and 61% of HCWs, respectively. Conclusions The number of nosocomial COVID-19 cases in our hospital was low. Compliance regarding mask wearing, hand hygiene and lockdown measures drastically reduced transmission of the virus. Monitoring of nosocomial COVID-19 cases during the first wave enabled us to determine to what extent the hygiene measures taken were effective and patients protected. Trial registration Study ethics approval was obtained retrospectively on 30 September 2020 (CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand, IRB 5891).
Published: 2020

6. Screening of hepatitis E in patients presenting for acute neurological disorders

Author: Sébastien Lhomme, Chantal Dumestre-Pérard, Vincent Leroy, Lorella Minotti, Emeline Lagrange, Patrice Morand, Jean-Luc Bosson, M. Lugosi, Claire Wintenberger, Roselyne Collomb-Muret, Aude Belbézier, Maxime Maignan, Damien Viglino, Françoise Sarrot-Reynauld, Sylvie Larrat, Perrine Dumanoir, Isabelle Boccon-Gibod, Alban Deroux, Carole Schwebel, A. Bosseray, Antoine Vilotitch, Mathieu Vaillant, Julien Lupo, Laurence Bouillet, Olivier Epaulard, B. Colombe, Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Universitaire [Grenoble] (CHU), Pôle Psychiatrie et Neurologie [Grenoble], Service d'immunologie [CHU Grenoble], CHU de Grenoble, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Département de virologie [Grenoble], Institut de biologie structurale (IBS - UMR 5075), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Biologie du Cancer et de l'Infection (BCI ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications Grenoble - UMR 5525 (TIMC-IMAG)
Subjects: 0301 basic medicine, Male, viruses, Neurological disorder, medicine.disease_cause, Serology, Hepatitis, 0302 clinical medicine, Hepatitis E virus, Seroepidemiologic Studies, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030212 general & internal medicine, Prospective Studies, Acute hepatitis, MESH: Acute Disease / epidemiology, Adult, Aged, Aged, 80 and over, Brachial Plexus Neuritis / epidemiology, Female, France / epidemiology, Guillain-Barre Syndrome / epidemiology, Hepatitis Antibodies / blood, Hepatitis E / blood, Hepatitis E / diagnosis, Hepatitis E / epidemiology, Hepatitis E / immunology, Hepatitis E virus / immunology, Humans Immunoglobulin M / blood, Middle Aged, Nervous System Diseases / epidemiology, Nervous System Diseases / immunology, RNA, Viral / blood, Reverse Transcriptase Polymerase Chain Reaction, Transaminases / blood, Young Adult, education.field_of_study, lcsh:Public aspects of medicine, virus diseases, General Medicine, Hepatitis E, 3. Good health, Infectious Diseases, Acute Disease, RNA, Viral, France, medicine.medical_specialty, 030106 microbiology, Population, Guillain-Barre Syndrome, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Internal medicine, medicine, Seroprevalence, Brachial Plexus Neuritis, Humans, lcsh:RC109-216, Hepatitis Antibodies, education, Transaminases, business.industry, Public Health, Environmental and Occupational Health, lcsh:RA1-1270, medicine.disease, Immunoglobulin M, Elevated transaminases, Nervous System Diseases, business
Abstract: International audience; Introduction: Hepatitis E virus (HEV) infection has been reported to be associated with neurological disor-ders. However, the real prevalence of acute hepatitis E in those diseases is still unknown. We determinedthe prevalence of anti-HEV IgM antibody in a population with acute non-traumatic, non-metabolic,non-vascular neurological injury.Method: A registry was created in Grenoble Hospital University from 2014 to 2018 to collect data onpatients with acute (
Published: 2020
Full Text: View/download PDF

7. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort

Author: Philippe Halfon, Jacques Izopet, Pascale Trimoulet, Caroline Scholtes, Sofiane Mohamed, Denis Ouzan, Laurent Chiche, Victor de Ledinghen, Hacène Khiri, Marc Bourlière, M.A. Thelu, Sophie Metivier, Guillaume Penaranda, Anne Plauzolles, Laurent Alric, Vincent Leroy, Fabien Zoulim, Sylvie Larrat, Florence Abravanel, ALPHABIO - Laboratoire de biologie médicale, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Institut de Recherche en Santé Digestive (IRSD ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Hôpital Michallon, Institut Arnault Tzanck, Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen [Fondation Ambroise Paré - Marseille], Centre Hospitalier Universitaire de Lyon (CHU Lyon), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Bordeaux [Bordeaux], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Hôpital Haut-Lévêque [CHU Bordeaux], Hôpital Saint-Joseph [Marseille], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT)
Subjects: Male, 0301 basic medicine, DNA Mutational Analysis, Viral Nonstructural Proteins / genetics, Drug Resistance, Hepacivirus, Drug resistance, Viral Nonstructural Proteins, Virological response, Viral Nonstructural Proteins / antagonists & inhibitors, 0302 clinical medicine, Medicine, Pharmacology (medical), Viral, Treatment Failure, Hepatitis C, Viral Load, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 3. Good health, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Treatment Outcome, Infectious Diseases, Antiviral Agents / pharmacology, Cohort, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Viral load, Hepacivirus / genetics, medicine.medical_specialty, Genotype, Antiviral Agents / therapeutic use, Antiviral Agents, 03 medical and health sciences, Pharmacotherapy, Drug Therapy, Internal medicine, Drug Resistance, Viral, Humans, NS5A, Pharmacology, business.industry, medicine.disease, 030104 developmental biology, Hepatitis C / virology, Hepacivirus / drug effects, Post treatment, Hepatitis C / drug therapy, business
Abstract: Background Recent data have suggested that failure to achieve sustained virological response with direct-acting antiviral therapy is usually due to relapse and is primarily associated with the emergence of resistance-associated substitutions. The aim of this study was to investigate the prevalence and characterization of non-structural-5A resistance-associated substitutions in patients infected with HCV genotypes 1, 3 and 4 treated by direct-acting antiviral therapy, including anti-non-structural-5A, and to characterize the pre-existing resistance-associated substitutions in subjects treated with anti-non-structural-5A inhibitors. Methods From January 2014 to March 2016, 2,995 patients infected with HCV genotypes 1, 3 and 4 were exposed to non-structural-5A inhibitors. Sequencing results at the time of virological failure were available for 61 patients; sequencing at baseline was available for 35 of these patients. Results Among the 35 patients with sequencing results available at baseline, 15 had no resistance-associated substitution, 16 had only one resistance-associated substitution, and 4 had more than one resistance-associated substitution. Resistance-associated substitutions were harbored in 57% of the sequences in the non-structural-5A region. Among the 61 patients sequenced at virological failure, 50 (82%) patients presented at least one resistance-associated substitutions inducing a high level of resistance to non-structural-5A inhibitors (>10-fold resistance). Conclusions This pooled analysis suggests that non-structural-5A resistance-associated substitutions screening should be recommended when considering retreatment with a non-structural-5A inhibitor regimen in patients who have previously experienced failed non-structural-5A treatment.
Published: 2017
Full Text: View/download PDF

8. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity

Author: Pascal Veillon, Evelyne Schvoerer, Joël Gozlan, Hélène Le Guillou-Guillemette, Sylvie Larrat, Françoise Lunel-Fabiani, Adeline Pivert, Vincent Mackiewicz, Véronique Brodard, Véronique Loustaud-Ratti, Vincent Thibault, Emmanuel Gordien, Sophie Alain, Alexandra Ducancelle, Jérôme Boursier, Sandrine Castelain, Sandrine Bertrais, Marianne Coste-Burel, Bénédicte Roquebert, Paul Calès, Sarah Maylin, Stéphane Chevaliez, and Viorica Balan
Subjects: Hepatitis B virus, medicine.medical_specialty, HBsAg, Mutation, Hepatology, business.industry, Gastroenterology, Hepatitis B, medicine.disease, medicine.disease_cause, Virology, 3. Good health, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Fibrosis, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, Hepatic fibrosis, business, Viral hepatitis
Abstract: BACKGROUND AND AIM The impact of basal core promoter (BCP) and precore (PC) mutants of the hepatitis B virus (HBV) on liver disease severity remains controversial. The aim of the present study was to screen BCP and PC mutations in 252 HBV surface antigen (HBsAg) positive carriers in France and to assess relationships between these mutations and severe fibrosis. METHODS Direct sequencing of the precore/core gene was used to detect A1762T/G1764A and G1757A mutations in the BCP and G1896A and G1899A mutations in the PC region. RESULTS The prevalences of A1762T/G1764A, G1757A, G1896A, and G1899A mutations were 34.1%, 38.7%, 54.9%, and 29.3% (P
Published: 2016
Full Text: View/download PDF

9. Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season

Author: Roselyne Collomb Muret, Anne Lebeugle, Valérie Guglielmetti, Sylvie Larrat, Virginie Forget, Prudence Mabiala Makele, Maxime Maignan, Julien Lupo, Damien Viglino, Maud Hablot, Patrice Morand, Nicolas Termoz Masson, Caroline Landelle, Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2 ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Emergency department [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de Virologie [Grenoble], Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Infection Control Unit [Grenoble], Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), This work was partly funded by Roche Diagnostics (http://www.roche-diagnostics.fr/), the industrial company that markets the cobas Liat system. MM received this grant., Laboratoire Hypoxie et Physiopathologies cardiovasculaires et respiratoires [Grenoble] (HP2), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), and Bodescot, Myriam
Subjects: 0301 basic medicine, Male, RNA viruses, Viral Diseases, Influenza Viruses, Critical Care and Emergency Medicine, Health Care Providers, Nurses, Artificial Gene Amplification and Extension, medicine.disease_cause, Roche Diagnostics, Pathology and Laboratory Medicine, Polymerase Chain Reaction, Biochemistry, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Interquartile range, Nucleic Acids, Influenza A virus, Medicine and Health Sciences, Medicine, 030212 general & internal medicine, Prospective Studies, Medical Personnel, Prospective cohort study, Aged, 80 and over, Multidisciplinary, Reverse Transcriptase Polymerase Chain Reaction, Middle Aged, 3. Good health, Professions, Infectious Diseases, Molecular Diagnostic Techniques, Medical Microbiology, Viral Pathogens, Viruses, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, Seasons, Pathogens, Emergency Service, Hospital, Research Article, Adult, medicine.medical_specialty, Science, Point-of-Care Systems, 030106 microbiology, Research and Analysis Methods, Microbiology, Specimen Handling, 03 medical and health sciences, Internal medicine, Virology, Influenza, Human, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Molecular Biology Techniques, Molecular Biology, Microbial Pathogens, Point of care, Aged, business.industry, Organisms, Biology and Life Sciences, Emergency department, Reverse Transcriptase-Polymerase Chain Reaction, Triage, Confidence interval, Influenza, Health Care, Influenza B virus, People and Places, Population Groupings, business, Orthomyxoviruses
Abstract: Study objectiveTo investigate the performance of a rapid RT-PCR assay to detect influenza A/B at emergency department admission.MethodsThis single-center prospective study recruited adult patients attending the emergency department for influenza-like illness. Triage nurses performed nasopharyngeal swab samples and ran rapid RT-PCR assays using a dedicated device (cobas Liat, Roche Diagnostics, Meylan, France) located at triage. The same swab sample was also analyzed in the department of virology using conventional RT-PCR techniques. Patients were included 24 hours-a-day, 7 days-a-week. The primary outcome was the diagnostic accuracy of the rapid RT-PCR assay performed at triage.ResultsA total of 187 patients were included over 11 days in January 2018. Median age was 70 years (interquartile range 44 to 84) and 95 (51%) were male. Nine (5%) assays had to be repeated due to failure of the first assay. The sensitivity of the rapid RT-PCR assay performed at triage was 0.98 (95% confidence interval (CI): 0.91-1.00) and the specificity was 0.99 (95% CI: 0.94-1.00). A total of 92 (49%) assays were performed at night-time or during the weekend. The median time from patient entry to rapid RT-PCR assay results was 46 [interquartile range 36-55] minutes.ConclusionRapid RT-PCR assay performed by nurses at triage to detect influenza A/B is feasible and highly accurate.
Published: 2019
Full Text: View/download PDF

10. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study

Author: Vincent Thibault, Benjamin Nemoz, Magali Bouvier-Alias, P. Marcellin, Françoise Lunel-Fabiani, Vincent Leroy, C. Henquell, Etienne Brochot, Patrice Morand, T. Semenova, Christopher Payan, Gilles Duverlie, S. Vallet, Pascale Trimoulet, Sylvie Larrat, L. Izquierdo, Gisèle Lagathu, A. M. Roque-Afonso, Sarah Maylin, Stéphane Chevaliez, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Pontchaillou [Rennes], Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), CHU Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Université Grenoble Alpes (UGA), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Liver Cirrhosis, Male, Databases, Factual, Epidemiology, Hepacivirus, medicine.disease_cause, Severity of Illness Index, Tertiary Care Centers, 0302 clinical medicine, Genotype, Prevalence, ComputingMilieux_MISCELLANEOUS, education.field_of_study, [SDE.IE]Environmental Sciences/Environmental Engineering, Incidence (epidemiology), Hepatitis C, 3. Good health, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, 030211 gastroenterology & hepatology, Female, France, Viral hepatitis, Adult, treatment-naive HCV, medicine.medical_specialty, Hepatitis C virus, [SDE.MCG]Environmental Sciences/Global Changes, Population, HCV genotypes, Statistics, Nonparametric, 03 medical and health sciences, Viral Proteins, Internal medicine, medicine, Humans, education, Retrospective Studies, Hepatitis, Original Paper, business.industry, fibrosis, Hepatitis C, Chronic, medicine.disease, [SDE.ES]Environmental Sciences/Environmental and Society, 030104 developmental biology, Logistic Models, Multivariate Analysis, [SDE.BE]Environmental Sciences/Biodiversity and Ecology, business
Abstract: Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral (DAA) combinations achieving high cure rates. Nevertheless, the cost of this treatment is still high and access to treatment in many countries has been preferentially reserved for patients with more severe fibrosis (F3 and F4). In this French nationwide study, we investigated the epidemiological characteristics and genotype distribution of hepatitis C virus (HCV) in treatment-naive patients with METAVIR fibrosis stages between F0 and F2 in order to identify patient profiles that became eligible for unrestricted treatment in a second period. Between 2015 and 2016 we collected data from nine French university hospitals on a total of 584 HCV positive patients with absent, mild or moderate liver fibrosis. The most represented genotypes were genotype 1b (159/584; 27.2%), followed by genotype 1a (150/584; 25.7%); genotype 3 (87/584: 14.9%); genotype 4 (80/584; 13.7%). Among genotype 4: 4a was predominantly encountered with 22 patients (27.5% of genotype 4). Genotypes 1b and 1a are currently the most frequent virus types present in treatment-naive patients with mild fibrosis in France. They can be readily cured using the available DAA. Nevertheless, non-a/non-d genotype 4 is also frequent in this population and clinical data on the efficacy of DAA on these subtypes is missing. The GEMHEP is the French group for study and evaluation of viral hepatitis on a national scale. Data collection on epidemiological and molecular aspects of viral hepatitis is performed on a regular basis in all main French teaching hospitals and serves as a basis for surveillance of these infections. Analysis and trends are regularly published on behalf of the GEMHEP group. Data collection was performed retrospectively over the 2015–2016 period, covering nine main university hospitals in France. A total of 584 hepatitis C positive patients were included in this study. Genotyping of the circulating viruses showed a high prevalence of genotypes 1b and 1a in our population. The epidemiology of hepatitis C is slowly changing in France, particularly as a consequence of the rise of ‘non-a non-d’ genotype 4 viruses mainly originating from African populations. More data concerning treatment efficacy of these genotypes is needed in order to guide clinical care.
Published: 2019
Full Text: View/download PDF

11. Innovative multiplexed point-of-care immunoassay applied to hepatitis B screening

Author: Paul Kauffmann, Pn Marche, Guillaume Blaire, Sarah Delshadi, Thomas Decaens, Patrice Morand, V. Masse, O. Cugat, Sylvie Larrat, Microbiology and Infectious Diseases, Sherbrooke University Hospital, Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Génie Electrique de Grenoble (G2ELab), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Institut de biologie structurale (IBS - UMR 5075 ), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Chadebec, Olivier, Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Subjects: medicine.diagnostic_test, business.industry, [SPI.NRJ]Engineering Sciences [physics]/Electric power, Biochemistry (medical), Clinical Biochemistry, General Medicine, Biochemistry, Virology, 3. Good health, Hepatitis B screening, Immunoassay, medicine, business, ComputingMilieux_MISCELLANEOUS, [SPI.NRJ] Engineering Sciences [physics]/Electric power, Point of care
Abstract: International audience
Published: 2019
Full Text: View/download PDF

12. Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures

Author: Sylvie Larrat, Jean-Dominique Poveda, Patrice Morand, Benjamin Nemoz, Vincent Leroy, Léa Roger, Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hôpital Michallon, Laboratoire CERBA [Saint Ouen l'Aumône], Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)
Subjects: RNA viruses, 0301 basic medicine, Genotyping Techniques, MESH: Reagent Kits, Diagnostic, lcsh:Medicine, Artificial Gene Amplification and Extension, Hepacivirus, medicine.disease_cause, Roche Diagnostics, Polymerase Chain Reaction, MESH: Genotype, Genotype, MESH: Sequence Analysis, RNA, Medicine, MESH: Hepacivirus, lcsh:Science, Asymptomatic Infections, Pathology and laboratory medicine, Sanger sequencing, Multidisciplinary, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], Hepatitis C virus, MESH: Real-Time Polymerase Chain Reaction, Viral Load, Medical microbiology, Subtyping, MESH: Hepatitis C, Chronic, 3. Good health, MESH: RNA, Viral, Viruses, symbols, RNA, Viral, Pathogens, MESH: Viral Load, Viral load, Research Article, MESH: Antiviral Agents, Genotyping, 030106 microbiology, MESH: Asymptomatic Infections, Research and Analysis Methods, Real-Time Polymerase Chain Reaction, Microbiology, Antiviral Agents, 03 medical and health sciences, symbols.namesake, Extraction techniques, Virology, MESH: Genotyping Techniques, Humans, Serologic Tests, Typing, Molecular Biology Techniques, Sequencing Techniques, Molecular Biology, Retrospective Studies, Medicine and health sciences, MESH: Humans, Flaviviruses, Sequence Analysis, RNA, business.industry, MESH: Serologic Tests, lcsh:R, Organisms, Viral pathogens, Automated Fluorescent Genotyping, Biology and Life Sciences, MESH: Retrospective Studies, Reverse Transcriptase-Polymerase Chain Reaction, Hepatitis C, Chronic, Hepatitis viruses, RNA extraction, Microbial pathogens, lcsh:Q, Reagent Kits, Diagnostic, business, Viral Transmission and Infection
Abstract: International audience; Direct-acting antiviral (DAA) drug performances depend on the viral genotype. So international recommendations give typing of the virus a prerequisite for treatment choice and patient management. Commercially available HCV genotyping kits are scarce and this analysis is often in-house using tedious PCRs and Sanger sequencing, leading to a lack of standardization. A newly commercialized HCV genotyping assay based on real-time PCR has been developed by Roche Diagnostics (Mannheim, Germany). We compared this new assay with our in-house PCRs -sequencing technique on 101 regular samples and 81 LiPA failures or low viral load samples. No genotype or 1a/1b subtype mismatch was observed. Two samples were misidentified at the subtype level without clinical impact. Three genotype 1b and two genotype 1a samples with low viral load could not be subtyped. Nevertheless, 13 (13%) samples from the regular panel and 35 (43%) from the more difficult-to-type panels failed to give results on first pass with the Roche kit. Failures were mostly associated with genotype 3 subtype a, with genotype 4 subtype non-a, or with viral loads
Published: 2018
Full Text: View/download PDF

13. Hepatitis E Virus in Acute Non-Traumatic, Non-Vascular Neurological Injury: A French Monocentric Prospective Study

Author: Claire Wintenberger, Maxime Maignan, Damien Viglino, Olivier Epaulard, Sylvie Larrat, Carole Schwebel, Françoise Sarrot-Reynauld, B. Colombe, Chantal Dumestre-Pérard, Lorella Minotti, Emeline Lagrange, Isabelle Boccond-Gibod, Alban Deroux, Maxime Lugosi, Laurence Bouillet, Perrine Dumanoir, Patrice Morand, A. Bosseray, Roselyne Collomb-Muret, Vincent Leroy, Jean-Luc Bosson, Julien Lupo, Antoine Vilotitch, Mathieu Vaillant, and Aude Belbézier
Subjects: medicine.medical_specialty, Neurological injury, Hepatitis E virus, business.industry, Non traumatic, Internal medicine, Medicine, business, Prospective cohort study, medicine.disease_cause
Published: 2018
Full Text: View/download PDF

14. Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation

Author: Anne Thiebaut-Bertrand, Sylvie Larrat, N Sturm, Sébastien Lhomme, Vincent Leroy, Martin Carre, J. Y. Cahn, Frédéric Garban, Patricia Pouzol, Patrice Morand, Institut de biologie structurale (IBS - UMR 5075 ), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Subjects: MESH: Fatal Outcome, Fatal outcome, medicine.medical_treatment, MESH: Allografts, Hematopoietic stem cell transplantation, Precursor Cell Lymphoblastic Leukemia Lymphoma, 03 medical and health sciences, 0302 clinical medicine, Fatal Outcome, medicine, MESH: Liver Failure, Acute, Humans, 030212 general & internal medicine, Fulminant hepatitis, ComputingMilieux_MISCELLANEOUS, MESH: Hematopoietic Stem Cell Transplantation, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation, MESH: Humans, MESH: Middle Aged, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], business.industry, MESH: Hepatitis E, Liver failure, Hematopoietic Stem Cell Transplantation, Hematology, Liver Failure, Acute, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hepatitis E, medicine.disease, Allografts, Virology, 3. Good health, Immunology, 030211 gastroenterology & hepatology, Female, Stem cell, business, MESH: Female
Abstract: International audience
Published: 2017
Full Text: View/download PDF

15. Prevalence and characterization of NS5A resistance associated variants (RAVs) in patients who relapsed following exposure to NS5A inhibitors

Author: Guillaume Penaranda, Philippe Halfon, Caroline Scholtès, Sofiane Mohamed, Vincent Leroy, Marc Bourlière, Denis Ouzan, Guillaume Pénaranda, Hacène Khiri, Laura Polverel, Fabien Zoulim, Marie-Ange Thélu, and Sylvie Larrat
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, Epidemiology, business.industry, Immunology, Public Health, Environmental and Occupational Health, Microbiology, QR1-502, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Infectious Diseases, Virology, Internal medicine, medicine, In patient, 030212 general & internal medicine, Public aspects of medicine, RA1-1270, business, NS5A
Published: 2016

16. Performance of an antigen–antibody combined assay for hepatitis C virus testing without venipuncture

Author: Marie-Noelle Hilleret, Cécile Bourdon, Cécile Garnaud, Myriam Blanc, Jean-Louis Quesada, Vincent Leroy, Raphaele Germi, P Leclercq, Jean-Pierre Zarski, Monique Baccard, Sophie Mathieu, Sylvie Larrat, Patrice Morand, and Anne Signori-Schmuck
Subjects: Adult, Male, Fingerstick, Point-of-Care Systems, Hepatitis C virus, medicine.disease_cause, Sensitivity and Specificity, Young Adult, Phlebotomy, Antigen, Virology, medicine, Humans, Saliva, Dried blood, Antigens, Viral, Aged, Immunoassay, Venipuncture, biology, Clinical Laboratory Techniques, business.industry, virus diseases, Hepatitis C Antibodies, Middle Aged, Serum samples, Hepatitis C, digestive system diseases, Blood, Infectious Diseases, biology.protein, Female, Antibody, business
Abstract: Background Hepatitis C virus (HCV) is underdiagnosed and therefore increasing the opportunities for HCV testing without venipuncture may be useful. Objectives We evaluated the analytical performance of a modified, commercially available, combined HCV antigen–antibody assay (cEIA) (Monolisa ® HCV-Ag-Ab-ULTRA) and a commercially available point-of-care (POC) device (OraQuick ® HCV) on fingerstick blood (FSB) and oral mucosal transudate (OMT). Study design FSB, OMT and serum samples were collected from 113 cases of HCV-antibody-positive patients and 88 HCV-antibody-negative controls. The HCV-antibody-positive group included 63 patients with quantifiable HCV-RNA (56%) and 17 HIV/HCV co-infected patients (15%). FSB and OMT specimens were collected as dried blood spots (DBSs) or with the OraSure collection system, before testing with cEIA. Results With FSB specimens, the cEIA and the POC device exhibited 100% specificity and 98.2% and 97.4% sensitivity, respectively. The specificity of the cEIA in FSB sharply decreased if stored 3 days at room temperature. With OMT specimens, the cEIA sensitivity (71.7%) and specificity (94.3%) were significantly lower than the performance of OraQuick ® HCV (sensitivity, 94.6%; specificity, 100%). The optical densities obtained with the cEIA in FSB and OMT were lower in HIV/HCV co-infected patients compared with HCV monoinfected patients. Conclusion The cEIA using FSB specimens collected on DBSs preserved in appropriate storage conditions was a reliable alternative, equivalent to the POC assay, for HCV testing without venipuncture. The cEIA was not adapted for HCV testing on OMT.
Published: 2012
Full Text: View/download PDF

17. Myasthenia Gravis Associated with Acute Hepatitis E Infection in Immunocompetent Woman

Author: Françoise Sarrot-Reynauld, Alban Deroux, Aude Belbézier, Sylvie Larrat, and Laurence Bouillet
Subjects: Microbiology (medical), Letter, ribavirin, Epidemiology, viruses, immunoglobulins, MuSK protein, lcsh:Medicine, hepatitis E virus, Disease, medicine.disease_cause, Transverse myelitis, lcsh:Infectious and parasitic diseases, chemistry.chemical_compound, Hepatitis E virus, antibodies, Medicine, hepatitis, lcsh:RC109-216, Letters to the Editor, IVIG, Hepatitis, myasthenia gravis, biology, business.industry, Ribavirin, lcsh:R, virus diseases, medicine.disease, Hepatitis E, immunocompetent, Myasthenia gravis, Infectious Diseases, chemistry, HEV, intravenous, Immunology, biology.protein, France, business, immunoglobulin
Abstract: To the Editor: Hepatitis E virus (HEV) is a common cause of acute hepatitis in developing countries. The course of acute hepatitis E is usually benign, except in pregnant women and in immunocompromised patients, who are prone to a lethal or chronic outcome of the disease. Since 2001, hepatitis E has been emerging in industrialized countries, and neurologic manifestations such as Guillain-Barre syndrome, brachial neuritis, transverse myelitis, and cranial nerve palsies have been reported in patients with acute or chronic forms of the disease (1–6). Most cases with neurologic manifestations have been characterized by infection with genotype 3 HEV. Data are not available to indicate whether this association between HEV infection and neurologic manifestations is related to a specific antigenic stimulus provided by HEV or is linked to the more comprehensive assessment for such neurologic conditions that is available in industrialized countries or to a reporting bias. We report a case of HEV infection in an immunocompetent woman who had muscle-specific kinase (MuSK) antibody–positive myasthenia gravis associated with HEV replication.
Published: 2014
Full Text: View/download PDF

18. Hepatitis E and neuralgic amyotrophy: Five cases and review of literature

Author: Sylvie Larrat, Françoise Sarrot-Reynauld, Anaïs Dartevel, Emmeline Lagrange, B. Colombe, Laurence Bouillet, A. Bosseray, Aude Belbézier, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Département de neurologie, and Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF)
Subjects: Parsonage–Turner syndrome, Adult, Male, Pediatrics, medicine.medical_specialty, Usually asymptomatic, Sex Factors, MESH: Sex Factors, Virology, medicine, Brachial Plexus Neuritis, Humans, Parsonage turner syndrome, MESH: Brachial Plexus Neuritis, MESH: Developed Countries, Neuralgic amyotrophy, MESH: Humans, MESH: Middle Aged, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], Acute hepatitis E, business.industry, Developed Countries, MESH: Hepatitis E, Mean age, Strong hepatitis E, MESH: Adult, Middle Aged, Hepatitis E, medicine.disease, Nervous system diseases, MESH: Immunoglobulin M, MESH: Male, 3. Good health, Surgery, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Infectious Diseases, Immunoglobulin M, Female, business, Brachial plexus, MESH: Female, Hepatitis E virus infection
Abstract: International audience; Hepatitis E virus infection - mainly genotype 3 - is increasingly common in industrialized countries. Infection is usually asymptomatic, but cases of central or peripheral neurological symptoms with hepatitis E have been described. The most frequent is Guillain-Barre but somes cases of neuralgic amyotrophy have been described. In our center, since 2010, we have identified five cases of neuralgic amyotrophy associated with acute hepatitis E in immunocompetent patients. For all these patients, neuralgic amyotrophy was diagnosed with electromyogram and positive IgM for hepatitis E, and detectable HEV RNA in 4 of the cases. Including our patients, we count 26 cases in literature. The mean age of the patients was 44 years old, with a large predominance of males (88%). The disorder is bilateral and asymmetric in 69% of cases. Peripheral nerves other than the brachial plexus were affected in 6 patients (23%). In industrialized countries, any neuralgic amyotrophy, particularly if there is bilateral, asymmetric associated with involvement of nerves outside the brachial plexus, should lead physicians to consider a diagnosis of acute hepatitis E.
Published: 2015
Full Text: View/download PDF

19. Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient

Author: Thomas Decaens, Thibaut Trouve-Buisson, Jean François Payen, Patricia Pouzol, Emmanuelle Loyrion, Sylvie Larrat, Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'Hématologie, CHU Grenoble, Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-imagerie fonctionnelle et métabolique (ANTE-INSERM U836, équipe 5), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), [GIN] Grenoble Institut des Neurosciences (GIN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Letter, Blood transfusion, Epidemiology, Opportunistic infection, MESH: Spleen, medicine.medical_treatment, viruses, opportunistic infection, lcsh:Medicine, 030204 cardiovascular system & hematology, medicine.disease_cause, jaundice, 0302 clinical medicine, Hepatitis E virus, Medicine, Platelet, MESH: Blood Platelets, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], MESH: Splenic Rupture, MESH: Cholecystitis, Acute, virus diseases, Jaundice, MESH: Ribs, 3. Good health, Infectious Diseases, trauma, 030211 gastroenterology & hepatology, medicine.symptom, Microbiology (medical), MESH: Antiviral Agents, MESH: Hepatitis E virus, injury, MESH: Shock, Septic, contaminated blood products, MESH: Blood Transfusion, hepatitis E virus, Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient, blood transfusion, MESH: Splenectomy, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Cholestasis, MESH: Ribavirin, MESH: Platelet Transfusion, lcsh:RC109-216, Letters to the Editor, Genotyping, transfusion, MESH: Humans, business.industry, MESH: Hepatitis E, lcsh:R, MESH: Blood Donors, MESH: Adult, medicine.disease, immunocompetent, MESH: Male, digestive system diseases, Platelet transfusion, HEV, Immunology, MESH: Respiratory Distress Syndrome, Adult, platelet transfusion, business, cholestasis, MESH: Antibodies, Viral
Abstract: International audience; Hepatitis E virus (HEV) infection causes acute liver disease, but severe infections are rare in immunocompetent patients. We describe a case of HEV infection in a previously healthy male trauma patient in France who received massive transfusions. Genotyping confirmed HEV in a transfused platelet pool and the donor.
Published: 2017
Full Text: View/download PDF

20. Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

Author: Françoise Stanke-Labesque, Jean-Pierre Zarski, Sylvie Larrat, Agnès Plages, Germain Bessard, and Claude Souvignet
Subjects: Adult, viruses, Hepacivirus, Hepatitis C virus, Biological Availability, Alpha interferon, Pharmacology, medicine.disease_cause, Antiviral Agents, High-performance liquid chromatography, chemistry.chemical_compound, Pharmacokinetics, Interferon, Ribavirin, Humans, Medicine, Pharmacology (medical), Chromatography, High Pressure Liquid, Interferon alfa, Aged, Chromatography, biology, business.industry, Interferon-alpha, virus diseases, Hepatitis C, Chronic, Middle Aged, biology.organism_classification, digestive system diseases, Treatment Outcome, Infectious Diseases, chemistry, business, medicine.drug
Abstract: Ribavirin in combination with alpha 2 interferon is the consensus treatment for chronic hepatitis C. However, recent preliminary pharmacological studies have suggested that the bioavailability of ribavirin displays great interindividual variability. In order to monitor serum ribavirin levels during combination treatment, we developed and validated a quantitative assay using an approach adaptable for routine hospital laboratories. The method involved solid-phase extraction on phenyl boronic acid cartridges followed by high-performance liquid chromatography with a C 18 -bonded silica column and a mobile phase containing 10 mM ammonium phosphate buffer (with the pH adjusted to 2.5) and UV detection (207 nm). The sensitivity, recovery, linearity of the calibration curve, intra- and interassay accuracies, precision, and stability at 4°C were consistent with its use in the laboratory routine. In addition, other nucleoside analogues sometimes used with ribavirin in patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus did not interfere with the quantification of ribavirin levels. The ribavirin concentration was quantified in 24 serum samples from patients with chronic hepatitis C treated with a combination of ribavirin and alpha 2 interferon. The mean serum ribavirin concentration was 2.67 ± 1.06 μg/ml ( n = 24) at week 12 of treatment (W12) and 3.24 ± 1.35 μg/ml ( n = 24) at week 24 of treatment (W24). In addition, ribavirin concentrations displayed high interindividual variabilities: the coefficients of variation of the serum ribavirin concentrations adjusted to the administered dose were 44 and 48% at W12 and W24, respectively. Moreover, the ribavirin concentration was higher in patients with a sustained virological response ( n = 11) than in patients with treatment failure ( n = 13), with significant intergroup differences at W12 ( P = 0.030) and W24 ( P = 0.049). The present study describes a simple analytical method for the quantification of ribavirin in human serum that could be a useful tool for the monitoring of ribavirin concentrations in HCV-infected patients in order to improve the efficacy and safety of therapy with ribavirin plus interferon.
Published: 2003
Full Text: View/download PDF

21. Severe Pneumocystis jirovecii pneumonia in an idiopathic CD4+ lymphocytopenia patient: case report and review of the literature

Author: Jean-Baptiste Kern, Clémence Minet, Laurence Bouillet, Pierre Flori, Marie-Pierre Brenier-Pinchart, Danièle Maubon, Hervé Pelloux, Sylvie Larrat, Bernabé F. F. Chumpitazi, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Unité de pneumologie, CHU Grenoble, Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), and VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)
Subjects: Microbiology (medical), medicine.medical_specialty, Early Relapse, Microbiology, Idiopathic CD4+ lymphocytopenia, trimethoprim-sulfamethoxazole, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, In patient, 030212 general & internal medicine, 0303 health sciences, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM], 030306 microbiology, business.industry, Mortality rate, Pneumocystis jirovecii Pneumonia, opportunistic infections, medicine.disease, 3. Good health, Pneumonia, Respiratory failure, Immunology, Hiv patients, Lymphocytopenia, business
Abstract: Introduction: When diagnosing Pneumocystis jirovecii pneumonia (PJP), the clinical suspicion must be confirmed by laboratory tests. PJP is rarely described in patients with idiopathic CD4+ lymphocytopenia (ICL), a rare T‐cell deficiency of unknown origin with persistently low levels of CD4+ T‐cells (
Published: 2014
Full Text: View/download PDF

22. Association between hepatitis E and neurological disorders: two case studies and literature review

Author: M. Vaillant, Jean-Paul Brion, L. Hyerle, Emilie Mosnier, Aude Belbézier, A. Deroux, Patricia Pavese, Sylvie Larrat, Patrice Morand, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Molécules bioactives, conception, isolement et synthèse (MBCIS), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Systèmes Agraires et Développement Rural - UP1102 (SADR), AgroParisTech, Service de Dermatologie et Vénérologie, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Department of Infectious Diseases, and University Hospital
Subjects: Adult, Male, Parsonage–Turner syndrome, MESH: Hepatitis E virus, viruses, Disease, Serology, Virology, Hepatitis E virus, Brachial Plexus Neuritis, Humans, Medicine, In patient, Encephalitis, Viral, Viremia, MESH: Viremia, MESH: Brachial Plexus Neuritis, MESH: Humans, business.industry, MESH: Hepatitis E, virus diseases, MESH: Adult, Hepatitis E, medicine.disease, digestive system diseases, MESH: Male, 3. Good health, MESH: Encephalitis, Viral, Cytolysis, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Infectious Diseases, Immunology, business, Viral hepatitis, Encephalitis
Abstract: International audience; Hepatitis E (HEV) is an emerging disease in our developed countries, but is not routinely tested for in case of liver cytolysis. However, a growing number of extra-hepatic manifestations of HEV infection associated with acute hepatitis are reported. In this article, we discuss two cases of HEV with neurological symptoms, one with encephalitis, and the other with Parsonage Turner syndrome. All these disorders appeared concomitantly with liver cytolysis and disappeared quickly, following the viral kinetics. Only twenty cases of neurological manifestation of HEV have been described before. The use of HEV serology in patients with concurrent liver cytolysis and neurological symptoms has to be improved.
Published: 2014

23. Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER)

Author: Caroline Scholtes, Pascale Trimoulet, Céline Dorival, J.-M. Pawlotsky, Sylvie Larrat, Fabrice Carrat, Jean-François Meritet, Laurence Bocket, Stanislas Pol, Stéphane Chevaliez, Edouard Tuaillon, Laboratoire de Virologie CHU Henri Mondor, Hôpital Pellegrin Tripode, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département de virologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Université Catholique de Lyon (UCLy) (UCLy), CIC - Mère Enfant Necker Cochin Paris Centre (CIC 1419), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Université catholique de Lille - Faculté de médecine et de maïeutique (UCL FMM), Université catholique de Lille (UCL), Service d'hépatologie médicale [CHU Cochin], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: 0301 basic medicine, Hepatology, business.industry, viruses, [SDV]Life Sciences [q-bio], virus diseases, biochemical phenomena, metabolism, and nutrition, Virology, digestive system diseases, 3. Good health, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Medicine, 030211 gastroenterology & hepatology, business, Direct acting
Abstract: International audience; Re-treatment of patients with decompensated chronic hepatitis C virus cirrhosis using 24 weeks of sofosbuvir and NS5A inhibitor, with or without ribavirin after failing a 12 week course
Published: 2017
Full Text: View/download PDF

24. Case report: detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident

Author: Patrice Morand, Wen Qin, Sylvie Larrat, Marie-Noëlle Hilleret, Monique Baccard, Philippe Zaoui, Alban Deroux, and Gaelle Billet
Subjects: Male, Hepatitis B virus, medicine.medical_treatment, Molecular Sequence Data, Hbv reactivation, Context (language use), Hepatitis b surface antigen, Brain Ischemia, Virology, medicine, Cytotoxic T cell, Humans, Amino Acid Sequence, Elderly patient, Aged, 80 and over, Chemotherapy, Cerebral vascular accident, Hepatitis B Surface Antigens, business.industry, virus diseases, Immunosuppression, Hepatitis B, digestive system diseases, Infectious Diseases, Amino Acid Substitution, Liver, Immunology, DNA, Viral, Virus Activation, business
Abstract: HBV reactivations are observed frequently in patients with past hepatitis B infection receiving cytotoxic and/or immunosuppressive chemotherapy for hemato-oncological malignancies or autoimmune diseases. Recent ischemic stroke was shown to induce immunodepression by misunderstood mechanisms. To our knowledge, the association between HBV reactivation and ischemic stroke has not been reported before. This study reports the case of an anti-HBs- and anti-HBc-positive patient who presented HBV reactivation in a context of recent ischemic stroke, with no other intercurrent iatrogenic phenomenon or usual immunosuppressive pathology. J. Med. Virol. 84:1897–1900, 2012. © 2012 Wiley Periodicals, Inc.
Published: 2012

25. Hepatitis E virus infection in sheltered homeless persons, France

Author: Mamadou Kaba, Philippe Colson, Sylvie Larrat, Stéphanie Gaillard, Monique Baccard, Lionel Piroth, Patrice Cacoub, Stanislas Pol, Christian Perronne, Fabrice Carrat, Patrice Morand, Hôpital Michallon, Agroécologie [Dijon], Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and Agence Nationale de la Recherche (ANR)
Subjects: Male, Microbiology (medical), medicine.medical_specialty, Epidemiology, viruses, [SDV]Life Sciences [q-bio], Population, lcsh:Medicine, virus, sheltered homeless person, medicine.disease_cause, lcsh:Infectious and parasitic diseases, Serology, injection drug use, Hepatitis E virus, medicine, Humans, Seroprevalence, [SDV.BV]Life Sciences [q-bio]/Vegetal Biology, lcsh:RC109-216, hepatitise, France, Risk factor, education, education.field_of_study, business.industry, homeless persons, autochthonous hepatitis, lcsh:R, Dispatch, virus diseases, Hepatitis C, medicine.disease, Hepatitis E, Virology, HEV transmission, digestive system diseases, Infectious Diseases, Ill-Housed Persons, [SDE]Environmental Sciences, business
Abstract: To the Editor: Kaba et al. (1) reported a seroprevalence of 11.6% for hepatitis E virus (HEV) among homeless persons in the city of Marseille, located in southern France, and a multivariate analysis suggested that injection drug use (IDU) was an independent risk factor for HEV transmission. We disagree with this reported finding. We conducted a retrospective subanalysis of results from a multicenter therapeutic trial assessing HEV seroprevalence among HIV/hepatitis C co-infected patients in France (2). Serum samples from 84 IDU patients, enrolled during 2000–2002 were stored at −80°C. The mean ± SD age of the patients was 39 ± 4 years; 53 (63%) were men, 19 (23%) were born outside France, and 38 (45%) were living in southern France. HEV antibodies were tested with the same assay as that used by Kaba et al. (1), and HEV RNA was detected by using a real-time reverse transcription PCR amplifying open reading frame 3 (3). None of the patients had detectable IgM against HEV or HEV RNA. Test results for 3 (3.6%) patients were positive for HEV IgG. Two of them lived in southern France, resulting in a 5.3% (2/38) HEV prevalence for IDU patients living in this region, where HEV IgG prevalence for healthy blood donors has reportedly ranged from 9% to 16.6% (4). The difference between our study, which demonstrated low HEV IgG prevalence in IDU patients, even in southern France, and the results from Kaba et al. (1) must be interpreted with caution because there were several epidemiologic differences between the 2 populations. Moreover, there is a risk for false-negative serologic results for HIV patients because of impaired immunity, and the predictive value of serologic testing is probably low because of the artificially low HEV prevalence reported for this population. Despite these limitations, our study suggests that the high prevalence of HEV infection among homeless persons in southern France was not influenced by IDU, but reflected the general epidemiology of HEV in this region.
Published: 2012
Full Text: View/download PDF

26. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin

Author: Jean-Pierre Zarski, Agnès Plages, Marie-Ange Thelu, Sylvie Larrat, Marion Levast, Patrice Morand, Sandrine Nicod, Alice Cheveau, Vincent Leroy, and Jean-Marie Seigneurin
Subjects: Adult, Male, HBsAg, Hepatitis B virus, Interferon alpha-2, medicine.disease_cause, Antiviral Agents, Polymerase Chain Reaction, Polyethylene Glycols, Liver disease, chemistry.chemical_compound, Pegylated interferon, Virology, Ribavirin, medicine, Prevalence, Humans, Hepatitis, Hepatitis B Surface Antigens, business.industry, virus diseases, Interferon-alpha, Hepatitis C, Hepatitis B, Hepatitis C, Chronic, Middle Aged, medicine.disease, digestive system diseases, Recombinant Proteins, Infectious Diseases, Blood, chemistry, Liver, Immunology, DNA, Viral, Female, France, Reagent Kits, Diagnostic, business, medicine.drug
Abstract: The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real-time PCR techniques are available commercially and can detect more reliably low HBV DNA levels. The aim of this study was to determine the prevalence of occult hepatitis B virus infection using the COBAS Taqman assay (Roche Diagnostics, Meylan, France) in the serum and liver of HBsAg negative patients with chronic hepatitis C and to evaluate its clinical consequences on liver pathology and its impact on the response to treatment with peg-IFNα and Ribavirin. HBV DNA detection was assessed retrospectively on 140 sera and 113 liver biopsies of HCV positive/HBsAg negative patients before treatment. A 4.4% (5/113) prevalence of occult hepatitis B was recorded in liver samples and in none of the sera. Anti-HBc was not detected in one, three of whom were sustained virological responders to treatment, one was relapsed responder and one was non-responder. Furthermore, in this cohort composed of 12% anti-HBs negative/anti-HBc positive and 20% anti-HBs positive/anti-HBc positive patients, anti-HBc was not associated with pre-therapeutic viral load, ALT serum levels, and histological activity or fibrosis. Using a commercial real-time PCR assay, we observed a low prevalence of occult B hepatitis. This, just as anti-HBC status, had no clinical impact in a large cohort of hepatitis C patients. It therefore does not appear useful to screen for occult hepatitis B in these patients with this test before beginning HCV treatment. J. Med. Virol. 82: 000–000, 2010. © 2010 Wiley-Liss, Inc. J. Med. Virol. 82: 747–754, 2010. © 2010 Wiley-Liss, Inc.
Published: 2010

27. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV–HCV co-infected patients on HCV therapy

Author: Benoit Martha, Stanislas Pol, Lionel Piroth, Christopher Payan, Isabelle Goderel, Sylvie Larrat, Patrice Cacoub, Firouzé Bani-Sadr, Patrice Morand, Fabrice Carrat, Christian Perronne, Françoise Lunel-Fabiani, Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de virologie moléculaire et structurale (LVMS), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Maladies infectieuses, Centre Hospitalier Chalon-sur-Saône William Morey, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Male, [SDV]Life Sciences [q-bio], HIV Infections, Comorbidity, Gastroenterology, Polyethylene Glycols, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Prevalence, 030212 general & internal medicine, biology, virus diseases, Hepatitis C, Hepatitis B, Flaviviridae Infections, Middle Aged, DNA Virus Infections, Recombinant Proteins, 3. Good health, Virus Diseases, Lentivirus, HCV, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, Viral disease, SEN-V, Adult, medicine.medical_specialty, Combination therapy, Hepatitis, Viral, Human, GB virus C, Interferon alpha-2, Antiviral Agents, 03 medical and health sciences, Pharmacotherapy, Hepatitis B, Chronic, Internal medicine, Ribavirin, medicine, Humans, GBV-C, Hepatitis, Torque teno virus, Hepatology, business.industry, Interferon-alpha, HIV, Occult hepatitis B, Hepatitis C, Chronic, medicine.disease, biology.organism_classification, Virology, digestive system diseases, business
Abstract: International audience; Background/AimsIt has been suggested that, in HIV–HCV co-infected patients, co-infections with other viruses may affect the response to HCV therapy. We aimed to assess the prevalence of GBV-C, SEN-V and occult HBV infections, their impact on HCV and HIV infections and on the response to HCV therapy in HIV–HCV co-infected patients. Methods Three-hundred and sixty eight patients were tested before starting interferon–ribavirin for the presence of occult hepatitis B DNA, GBV-C RNA and SEN-V DNA by using real time PCR. Clinical, immunological, virological, histological characteristics and response to HCV therapy were compared according to the presence or not of each viral co-infection. Results HBV DNA, GBV-C RNA and SEN-V DNA were found in 5 (1.4%, CI95%: 0.2–2.4%), 104 (29.9%, CI95%: 25.1–34.7%) and 209 patients (57.9%, CI95%: 52.8–63.0%), respectively. GBV-C positive patients had significantly higher CD4 count at baseline, during and after HCV therapy, even after stratification on antiretroviral treatment. No other significant difference was observed according to the presence or not of GBV-C or SEN-V co-infection, in particular regarding virological responses to HCV combination therapy. Conclusions There is no reason to withhold HCV therapy in HIV infected patients who have access to HAART, because of occult HBV, GBV-C or SEN-V co-infections.
Published: 2008
Full Text: View/download PDF

28. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs

Author: Julien Lupo, Patrice Morand, Jean-Marie Seigneurin, Sandrine Nicod, Raphaële Germi, Marie-Noëlle Hilleret, Sylvie Larrat, Jean-Pierre Zarski, Laboratoire de virologie moléculaire et structurale (LVMS), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Département de Gastroentérologie et hépatologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Duperray, Alain, and Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, Combination therapy, medicine.drug_class, Case Report, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Internal medicine, medicine, Adefovir, Dual therapy, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, 030304 developmental biology, 0303 health sciences, Hepatology, business.industry, Lamivudine, virus diseases, Resistance mutation, Virology, digestive system diseases, 3. Good health, 030211 gastroenterology & hepatology, Antiviral drug, business, medicine.drug
Abstract: International audience; ABSTRACT: BACKGROUND: Sequential monotherapies of nucleotide analogs used in chronic hepatitis B treatment can lead to the selection of a resistance mutation to each antiviral drug. CASE PRESENTATION: A patient with chronic hepatitis B was successively treated with lamivudine monotherapy, lamivudine-adefovir dual therapy, adefovir monotherapy and again with an adefovir-lamivudine dual therapy. Lamivudine-associated mutations (rtL180M and rtM204V/I) followed by adefovir-associated mutations (rtN236T and rtA181V) emerged during the two monotherapy regimens. Despite the presence of rtM204V/I, rtA181V, and rtN236T mutations at the beginning of the second dual therapy, sustained biochemical and virological responses have been observed thus far after 23 months. CONCLUSION: This case illustrates that rtM204V/I, rtA181V, and rtN236T resistance mutations can coexist in a patient but do not preclude the recycling of lamivudine and adefovir in combination therapy, when no other therapeutic choices are available.
Published: 2008
Full Text: View/download PDF

29. Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors

Author: Sofiane Mohamed, Caroline Scholtes, Vincent Leroy, M. Bourlière, Guillaume Penaranda, Sylvie Larrat, Denis Ouzan, L. Polverel, H. Khiri, Philippe Halfon, M.A. Thelu, and Fabien Zoulim
Subjects: Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, In patient, NS5A, business
Published: 2016
Full Text: View/download PDF

30. P1091 MONITORING THE IMMUNOMODULATORY EFFECTS OF PEGYLATED INTERFERON α-2a THERAPY IN PATIENTS WITH CHRONIC HBV INFECTION, AN IMMUNOLOGICAL SUB-STUDY OF ANRS HB06 PEGAN TRIAL

Author: J. Bruder-Costa, J. Plumas, Tania Dufeu-Duchesne, Sylvie Larrat, Vincent Leroy, Jean-Pierre Zarski, and C. Aspord
Subjects: Hepatology, business.industry, Medicine, Pegylated interferon α, In patient, business, Virology
Published: 2014
Full Text: View/download PDF

31. 363 VIROLOGICAL CHARACTERISTICS OF A LARGE PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC HEPATITIS B NEWLY SEEN IN HEPATOLOGY REFERENCE CENTERS IN FRANCE IN 2008-2010

Author: V. Brodard, C. Larsen, Sylvie Larrat, Christophe Rodriguez, Caroline Semaille, Cécile Brouard, J.-M. Pawlotsky, Stéphane Chevaliez, and P. Chevallier
Subjects: medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Internal medicine, medicine, business, Prospective cohort study, Gastroenterology
Published: 2011
Full Text: View/download PDF

32. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

Author: Marie Noelle Hilleret, Françoise Stanke-Labesque, Vincent Leroy, and Sylvie Larrat
Subjects: Virological response, Hepatology, business.industry, Medicine, Hepatitis B, Antiviral treatment, business, medicine.disease, Virology
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

32 results on '"Sylvie Larrat"'

1. Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

2. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

3. Evaluation of six commercial SARS-CoV-2 rapid antigen tests in nasopharyngeal swabs: better knowledge for better patient management?

4. Is it possible to hospitalize patients in multiple-bed room without increasing the risk of hospital-acquired influenza? Description of a pragmatic preventive strategy in a French university hospital

5. SARS-CoV-2 nosocomial infection acquired in a French university hospital during the 1st wave of the Covid-19 pandemic, a prospective study

6. Screening of hepatitis E in patients presenting for acute neurological disorders

7. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort

8. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity

9. Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season

10. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study

11. Innovative multiplexed point-of-care immunoassay applied to hepatitis B screening

12. Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures

13. Hepatitis E Virus in Acute Non-Traumatic, Non-Vascular Neurological Injury: A French Monocentric Prospective Study

14. Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation

15. Prevalence and characterization of NS5A resistance associated variants (RAVs) in patients who relapsed following exposure to NS5A inhibitors

16. Performance of an antigen–antibody combined assay for hepatitis C virus testing without venipuncture

17. Myasthenia Gravis Associated with Acute Hepatitis E Infection in Immunocompetent Woman

18. Hepatitis E and neuralgic amyotrophy: Five cases and review of literature

19. Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient

20. Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

21. Severe Pneumocystis jirovecii pneumonia in an idiopathic CD4+ lymphocytopenia patient: case report and review of the literature

22. Association between hepatitis E and neurological disorders: two case studies and literature review

23. Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER)

24. Case report: detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident

25. Hepatitis E virus infection in sheltered homeless persons, France

26. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin

27. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV–HCV co-infected patients on HCV therapy

28. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs

29. Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors

30. P1091 MONITORING THE IMMUNOMODULATORY EFFECTS OF PEGYLATED INTERFERON α-2a THERAPY IN PATIENTS WITH CHRONIC HBV INFECTION, AN IMMUNOLOGICAL SUB-STUDY OF ANRS HB06 PEGAN TRIAL

31. 363 VIROLOGICAL CHARACTERISTICS OF A LARGE PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC HEPATITIS B NEWLY SEEN IN HEPATOLOGY REFERENCE CENTERS IN FRANCE IN 2008-2010

32. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

32 results on '"Sylvie Larrat"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources